oxford biomedica (uk) limited
oxford biomedica (uk) limited Company Information
Company Number
03028927
Website
www.oxfordbiomedica.co.ukRegistered Address
windrush court transport way, oxford, OX4 6LT
Industry
Research and experimental development on biotechnology
Telephone
01865783000
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
oxford biomedica plc 100%
oxford biomedica (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of OXFORD BIOMEDICA (UK) LIMITED at £278.1m based on a Turnover of £116.3m and 2.39x industry multiple (adjusted for size and gross margin).
oxford biomedica (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of OXFORD BIOMEDICA (UK) LIMITED at £460.1m based on an EBITDA of £45.5m and a 10.11x industry multiple (adjusted for size and gross margin).
oxford biomedica (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of OXFORD BIOMEDICA (UK) LIMITED at £0 based on Net Assets of £-127.3m and 2.15x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Oxford Biomedica (uk) Limited Overview
Oxford Biomedica (uk) Limited is a live company located in oxford, OX4 6LT with a Companies House number of 03028927. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in March 1995, it's largest shareholder is oxford biomedica plc with a 100% stake. Oxford Biomedica (uk) Limited is a mature, mega sized company, Pomanda has estimated its turnover at £116.3m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Oxford Biomedica (uk) Limited Health Check
Pomanda's financial health check has awarded Oxford Biomedica (Uk) Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 3 areas for improvement. Company Health Check FAQs
4 Strong
5 Regular
3 Weak
Size
annual sales of £116.3m, make it larger than the average company (£3.5m)
£116.3m - Oxford Biomedica (uk) Limited
£3.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 22%, show it is growing at a faster rate (14.1%)
22% - Oxford Biomedica (uk) Limited
14.1% - Industry AVG
Production
with a gross margin of 50.6%, this company has a comparable cost of product (53%)
50.6% - Oxford Biomedica (uk) Limited
53% - Industry AVG
Profitability
an operating margin of 27.5% make it more profitable than the average company (-0.4%)
27.5% - Oxford Biomedica (uk) Limited
-0.4% - Industry AVG
Employees
with 810 employees, this is above the industry average (44)
810 - Oxford Biomedica (uk) Limited
44 - Industry AVG
Pay Structure
on an average salary of £75.4k, the company has an equivalent pay structure (£77.9k)
£75.4k - Oxford Biomedica (uk) Limited
£77.9k - Industry AVG
Efficiency
resulting in sales per employee of £143.5k, this is equally as efficient (£136.2k)
£143.5k - Oxford Biomedica (uk) Limited
£136.2k - Industry AVG
Debtor Days
it gets paid by customers after 133 days, this is later than average (51 days)
133 days - Oxford Biomedica (uk) Limited
51 days - Industry AVG
Creditor Days
its suppliers are paid after 74 days, this is close to average (70 days)
74 days - Oxford Biomedica (uk) Limited
70 days - Industry AVG
Stock Days
it holds stock equivalent to 53 days, this is in line with average (48 days)
53 days - Oxford Biomedica (uk) Limited
48 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 15 weeks, this is less cash available to meet short term requirements (35 weeks)
15 weeks - Oxford Biomedica (uk) Limited
35 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 155.4%, this is a higher level of debt than the average (50%)
155.4% - Oxford Biomedica (uk) Limited
50% - Industry AVG
OXFORD BIOMEDICA (UK) LIMITED financials
Oxford Biomedica (Uk) Limited's latest turnover from December 2022 is £116.3 million and the company has net assets of -£127.3 million. According to their latest financial statements, Oxford Biomedica (Uk) Limited has 810 employees and maintains cash reserves of £101.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 116,267,000 | 142,797,000 | 87,728,000 | 64,060,000 | 66,778,000 | 37,590,000 | 27,776,000 | 15,909,000 | 13,618,000 | 5,375,000 | 7,756,000 | 7,718,000 | 11,153,000 | 19,120,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 57,495,000 | 60,157,000 | 41,655,000 | 35,723,000 | 22,763,000 | 18,442,000 | 11,835,000 | 5,839,000 | 4,416,000 | 1,140,000 | 667,000 | 555,000 | -593,000 | 437,000 |
| Gross Profit | 58,772,000 | 82,640,000 | 46,073,000 | 28,337,000 | 44,015,000 | 19,148,000 | 15,941,000 | 10,070,000 | 9,202,000 | 4,235,000 | 7,089,000 | 7,163,000 | 11,746,000 | 18,683,000 |
| Admin Expenses | 26,834,000 | 59,478,000 | 49,872,000 | 41,558,000 | 28,576,000 | 23,609,000 | 25,473,000 | 20,792,000 | 19,617,000 | 16,461,000 | 17,857,000 | 21,631,000 | 23,725,000 | 24,416,000 |
| Operating Profit | 31,938,000 | 23,162,000 | -3,799,000 | -13,221,000 | 15,439,000 | -4,461,000 | -9,532,000 | -10,722,000 | -10,415,000 | -12,226,000 | -10,768,000 | -14,468,000 | -11,979,000 | -5,733,000 |
| Interest Payable | 1,034,000 | 888,000 | 912,000 | 6,526,000 | 8,972,000 | 9,422,000 | 9,028,000 | 2,925,000 | 69,000 | 4,000 | 68,000 | 99,000 | 111,000 | 116,000 |
| Interest Receivable | 643,000 | 0 | 34,000 | 104,000 | 71,000 | 3,329,000 | 34,000 | 26,000 | 53,000 | 64,000 | 140,000 | 144,000 | 222,000 | 670,000 |
| Pre-Tax Profit | 31,547,000 | 22,274,000 | -4,677,000 | -19,643,000 | 6,538,000 | -10,554,000 | -18,526,000 | -13,621,000 | -10,431,000 | -12,166,000 | -10,696,000 | -14,423,000 | -11,868,000 | -5,179,000 |
| Tax | -975,000 | -869,000 | 685,000 | 5,593,000 | 1,399,000 | 2,744,000 | 3,666,000 | 3,963,000 | 2,087,000 | 1,642,000 | 1,617,000 | 1,723,000 | 1,565,000 | 1,644,000 |
| Profit After Tax | 30,572,000 | 21,405,000 | -3,992,000 | -14,050,000 | 7,937,000 | -7,810,000 | -14,860,000 | -9,658,000 | -8,344,000 | -10,524,000 | -9,079,000 | -12,700,000 | -10,303,000 | -3,535,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 30,572,000 | 21,405,000 | -3,992,000 | -14,050,000 | 7,937,000 | -7,810,000 | -14,860,000 | -9,658,000 | -8,344,000 | -10,524,000 | -9,079,000 | -12,700,000 | -10,303,000 | -3,535,000 |
| Employee Costs | 61,094,000 | 53,842,000 | 45,176,000 | 33,589,000 | 25,207,000 | 17,989,000 | 15,930,000 | 11,290,000 | 7,876,000 | 6,277,000 | 5,985,000 | 5,602,000 | 8,598,000 | 9,000,000 |
| Number Of Employees | 810 | 759 | 609 | 500 | 377 | 295 | 247 | 196 | 113 | 95 | 82 | 84 | 71 | 68 |
| EBITDA* | 45,519,000 | 35,597,000 | 5,821,000 | -7,434,000 | 19,796,000 | -86,000 | -5,857,000 | -9,095,000 | -9,316,000 | -11,159,000 | -9,805,000 | -13,683,000 | -10,581,000 | -5,733,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 64,015,000 | 73,333,000 | 75,909,000 | 65,537,000 | 46,757,000 | 28,324,000 | 28,171,000 | 24,396,000 | 8,944,000 | 4,070,000 | 3,902,000 | 4,209,000 | 580,000 | 630,000 |
| Intangible Assets | 9,000 | 52,000 | 73,000 | 95,000 | 117,000 | 97,000 | 1,330,000 | 1,743,000 | 2,106,000 | 2,633,000 | 2,931,000 | 3,106,000 | 6,683,000 | 11,119,000 |
| Investments & Other | 0 | 0 | 0 | 0 | 10,966,000 | 2,954,000 | 657,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 3,585,000 | 3,605,000 | 3,605,000 | 3,605,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 64,024,000 | 73,385,000 | 75,982,000 | 65,632,000 | 42,874,000 | 28,421,000 | 29,501,000 | 26,139,000 | 11,050,000 | 6,703,000 | 6,833,000 | 7,315,000 | 7,263,000 | 11,749,000 |
| Stock & work in progress | 8,440,000 | 9,521,000 | 6,912,000 | 2,579,000 | 4,251,000 | 3,332,000 | 2,202,000 | 2,706,000 | 1,407,000 | 680,000 | 0 | 0 | 0 | 0 |
| Trade Debtors | 42,460,000 | 35,945,000 | 43,722,000 | 12,766,000 | 15,408,000 | 14,387,000 | 4,888,000 | 8,529,000 | 3,961,000 | 1,677,000 | 715,000 | 187,000 | 1,760,000 | 88,000 |
| Group Debtors | 0 | 0 | 0 | 0 | 226,000 | 226,000 | 226,000 | 226,000 | 226,000 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 12,780,000 | 8,984,000 | 6,974,000 | 17,464,000 | 6,292,000 | 2,693,000 | 2,013,000 | 2,390,000 | 1,182,000 | 913,000 | 977,000 | 2,380,000 | 2,026,000 | 4,331,000 |
| Cash | 101,858,000 | 47,315,000 | 23,113,000 | 16,242,000 | 32,234,000 | 14,298,000 | 9,806,000 | 9,355,000 | 12,896,000 | 2,119,000 | 8,125,000 | 6,770,000 | 6,555,000 | 6,711,000 |
| misc current assets | 23,000 | 74,000 | 0 | 0 | 2,446,000 | 2,232,000 | 3,000,000 | 2,721,000 | 2,000,000 | 1,500,000 | 6,863,000 | 9,141,000 | 6,934,000 | 20,769,000 |
| total current assets | 165,561,000 | 102,397,000 | 84,498,000 | 57,121,000 | 65,743,000 | 37,168,000 | 22,135,000 | 25,927,000 | 21,672,000 | 6,889,000 | 16,680,000 | 18,478,000 | 17,275,000 | 31,899,000 |
| total assets | 229,585,000 | 175,782,000 | 160,480,000 | 122,753,000 | 108,617,000 | 65,589,000 | 51,636,000 | 52,066,000 | 32,722,000 | 13,592,000 | 23,513,000 | 25,793,000 | 24,538,000 | 43,648,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 11,754,000 | 5,260,000 | 19,582,000 | 7,311,000 | 3,746,000 | 3,682,000 | 1,576,000 | 3,588,000 | 2,787,000 | 1,218,000 | 878,000 | 1,195,000 | 1,270,000 | 1,961,000 |
| Group/Directors Accounts | 292,658,000 | 287,802,000 | 276,576,000 | 262,739,000 | 209,326,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 975,000 | 853,000 | 4,475,000 | 482,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 33,180,000 | 27,043,000 | 28,264,000 | 21,039,000 | 24,646,000 | 17,999,000 | 7,564,000 | 9,556,000 | 9,319,000 | 5,659,000 | 5,978,000 | 8,266,000 | 9,108,000 | 12,979,000 |
| total current liabilities | 338,567,000 | 320,958,000 | 328,897,000 | 291,571,000 | 237,718,000 | 21,681,000 | 9,140,000 | 13,144,000 | 12,106,000 | 6,877,000 | 6,856,000 | 9,461,000 | 10,378,000 | 14,940,000 |
| loans | 22,964,000 | 16,976,000 | 18,740,000 | 15,814,000 | 291,632,000 | 264,748,000 | 254,004,000 | 229,390,000 | 175,899,000 | 152,877,000 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 11,482,000 | 8,488,000 | 9,370,000 | 7,907,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 1,069,000 | 1,760,000 | 2,515,000 | 3,310,000 | 6,434,000 | 0 | 0 | 0 | 0 | 0 | 0 | 170,000 | 4,201,000 | 9,024,000 |
| other liabilities | 76,000 | 92,000 | 1,003,000 | 1,695,000 | 0 | 0 | 0 | 0 | 0 | 0 | 152,668,000 | 143,443,000 | 125,010,000 | 125,007,000 |
| provisions | 11,338,000 | 12,488,000 | 11,678,000 | 10,890,000 | 5,388,000 | 1,260,000 | 1,244,000 | 1,066,000 | 1,070,000 | 1,064,000 | 1,020,000 | 1,002,000 | 914,000 | 840,000 |
| total long term liabilities | 18,296,000 | 16,584,000 | 18,727,000 | 18,357,000 | 259,607,000 | 228,514,000 | 220,237,000 | 202,668,000 | 175,434,000 | 153,409,000 | 153,178,000 | 144,114,000 | 129,668,000 | 134,451,000 |
| total liabilities | 356,863,000 | 337,542,000 | 347,624,000 | 309,928,000 | 497,325,000 | 250,195,000 | 229,377,000 | 215,812,000 | 187,540,000 | 160,286,000 | 160,034,000 | 153,575,000 | 140,046,000 | 149,391,000 |
| net assets | -127,278,000 | -161,760,000 | -187,144,000 | -187,175,000 | -388,708,000 | -184,606,000 | -177,741,000 | -163,746,000 | -154,818,000 | -146,694,000 | -136,521,000 | -127,782,000 | -115,508,000 | -105,743,000 |
| total shareholders funds | -127,278,000 | -161,760,000 | -187,144,000 | -187,175,000 | -175,382,000 | -184,606,000 | -177,741,000 | -163,746,000 | -154,818,000 | -146,694,000 | -136,521,000 | -127,782,000 | -115,508,000 | -105,743,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 31,938,000 | 23,162,000 | -3,799,000 | -13,221,000 | 15,439,000 | -4,461,000 | -9,532,000 | -10,722,000 | -10,415,000 | -12,226,000 | -10,768,000 | -14,468,000 | -11,979,000 | -5,733,000 |
| Depreciation | 13,560,000 | 12,435,000 | 9,598,000 | 5,765,000 | 4,332,000 | 4,113,000 | 3,340,000 | 1,264,000 | 703,000 | 671,000 | 593,000 | 335,000 | 699,000 | 0 |
| Amortisation | 21,000 | 0 | 22,000 | 22,000 | 25,000 | 262,000 | 335,000 | 363,000 | 396,000 | 396,000 | 370,000 | 450,000 | 699,000 | 0 |
| Tax | -975,000 | -869,000 | 685,000 | 5,593,000 | 1,399,000 | 2,744,000 | 3,666,000 | 3,963,000 | 2,087,000 | 1,642,000 | 1,617,000 | 1,723,000 | 1,565,000 | 1,644,000 |
| Stock | -1,081,000 | 2,609,000 | 4,333,000 | -1,672,000 | 919,000 | 1,130,000 | -504,000 | 1,299,000 | 727,000 | 680,000 | 0 | 0 | 0 | 0 |
| Debtors | 10,291,000 | -5,767,000 | 20,466,000 | 3,023,000 | 13,506,000 | 10,179,000 | -4,018,000 | 5,776,000 | 2,779,000 | 898,000 | -875,000 | -1,219,000 | -633,000 | 4,419,000 |
| Creditors | 6,494,000 | -14,322,000 | 12,271,000 | 3,565,000 | 64,000 | 2,106,000 | -2,012,000 | 801,000 | 1,569,000 | 340,000 | -317,000 | -75,000 | -691,000 | 1,961,000 |
| Accruals and Deferred Income | 5,446,000 | -1,976,000 | 6,430,000 | -6,731,000 | 13,081,000 | 10,435,000 | -1,992,000 | 237,000 | 3,660,000 | -319,000 | -2,458,000 | -4,873,000 | -8,694,000 | 22,003,000 |
| Deferred Taxes & Provisions | -1,150,000 | 810,000 | 788,000 | 5,502,000 | 4,128,000 | 16,000 | 178,000 | -4,000 | 6,000 | 44,000 | 18,000 | 88,000 | 74,000 | 840,000 |
| Cash flow from operations | 46,124,000 | 22,398,000 | 1,196,000 | -856,000 | 24,043,000 | 3,906,000 | -1,495,000 | -11,173,000 | -5,500,000 | -11,030,000 | -10,070,000 | -15,601,000 | -17,694,000 | 16,296,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | -10,966,000 | 8,012,000 | 2,297,000 | 657,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 4,856,000 | 11,226,000 | 13,837,000 | 53,413,000 | 209,326,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 5,988,000 | -1,764,000 | 2,926,000 | -275,818,000 | 26,884,000 | 10,744,000 | 24,614,000 | 53,491,000 | 23,022,000 | 152,877,000 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 3,116,000 | -4,504,000 | 5,456,000 | 8,389,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | -16,000 | -911,000 | -692,000 | 1,695,000 | 0 | 0 | 0 | 0 | 0 | -152,668,000 | 9,225,000 | 18,433,000 | 3,000 | 125,007,000 |
| share issue | ||||||||||||||
| interest | -391,000 | -888,000 | -878,000 | -6,422,000 | -8,901,000 | -6,093,000 | -8,994,000 | -2,899,000 | -16,000 | 60,000 | 72,000 | 45,000 | 111,000 | 554,000 |
| cash flow from financing | 17,463,000 | 7,138,000 | 24,672,000 | -216,486,000 | 228,596,000 | 5,596,000 | 16,485,000 | 51,322,000 | 23,226,000 | 620,000 | 9,637,000 | 18,904,000 | 652,000 | 23,353,000 |
| cash and cash equivalents | ||||||||||||||
| cash | 54,543,000 | 24,202,000 | 6,871,000 | -15,992,000 | 17,936,000 | 4,492,000 | 451,000 | -3,541,000 | 10,777,000 | -6,006,000 | 1,355,000 | 215,000 | -156,000 | 6,711,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 54,543,000 | 24,202,000 | 6,871,000 | -15,992,000 | 17,936,000 | 4,492,000 | 451,000 | -3,541,000 | 10,777,000 | -6,006,000 | 1,355,000 | 215,000 | -156,000 | 6,711,000 |
oxford biomedica (uk) limited Credit Report and Business Information
Oxford Biomedica (uk) Limited Competitor Analysis
Perform a competitor analysis for oxford biomedica (uk) limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
oxford biomedica (uk) limited Ownership
OXFORD BIOMEDICA (UK) LIMITED group structure
Oxford Biomedica (Uk) Limited has 1 subsidiary company.
Ultimate parent company
1 parent
OXFORD BIOMEDICA (UK) LIMITED
03028927
1 subsidiary
oxford biomedica (uk) limited directors
Oxford Biomedica (Uk) Limited currently has 3 directors. The longest serving directors include Mr Stuart Paynter (Aug 2017) and Mr Stuart Paynter (Aug 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Stuart Paynter | 50 years | Aug 2017 | - | Director | |
| Mr Stuart Paynter | 52 years | Aug 2017 | - | Director | |
| Dr Frank Mathias | 61 years | Mar 2023 | - | Director |
P&L
December 2022turnover
116.3m
-19%
operating profit
31.9m
+38%
gross margin
50.6%
-12.65%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
-127.3m
-0.21%
total assets
229.6m
+0.31%
cash
101.9m
+1.15%
net assets
Total assets minus all liabilities
oxford biomedica (uk) limited company details
company number
03028927
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
March 1995
age
29
accounts
Full Accounts
ultimate parent company
previous names
oxford biomedica limited (October 1996)
oxford genetic therapeutics limited (March 1996)
incorporated
UK
address
windrush court transport way, oxford, OX4 6LT
last accounts submitted
December 2022
oxford biomedica (uk) limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 7 charges/mortgages relating to oxford biomedica (uk) limited. Currently there are 2 open charges and 5 have been satisfied in the past.
oxford biomedica (uk) limited Companies House Filings - See Documents
| date | description | view/download |
|---|
